The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Mitomycin C was reviewed in this journal 25 years ago and an update of its clinical
usefulness is appropriate. The current review is based on representative publications …

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of
the metal, its oxidation state, the types and number of coordinated ligands and the …

Background We conducted a randomized study to determine whether any of three
chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced …

We analyzed the 2,531-patient Southwest Oncology Group extensive-stage non-small-cell
lung cancer (ENSCLC) data base from 1974 to 1988 to (1) assess the interactions of host-or …

ContextRandomized trials have demonstrated that adding a drug to a single-agent or to a 2-
agent regimen increased the tumor response rate in patients with advanced non–small-cell …

PURPOSE Cisplatin has played a major role in the treatment of non-small-cell lung cancer
(NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) …

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival
advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To …

Most anticancer drugs are effective only in subgroups of patients, and our current
understanding of tumor biology does not allow us to predict accurately which patient will …

PURPOSE: To determine the changes in clinical trials and outcomes of patients with
advanced-stage non–small-cell lung cancer (NSCLC) treated on phase III randomized trials …